share_log

HC Wainwright & Co. Maintains Buy on Viracta Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. Maintains Buy on Viracta Therapeutics, Lowers Price Target to $4

HC Wainwright & Co.维持对Viracta Therapeutics的买入,将目标股价下调至4美元
Benzinga ·  01/05 19:17

HC Wainwright & Co. analyst Robert Burns maintains Viracta Therapeutics (NASDAQ:VIRX) with a Buy and lowers the price target from $10 to $4.

HC Wainwright & Co. 分析师罗伯特·伯恩斯维持Viracta Therapeutics(纳斯达克股票代码:VIRX)的买入并将目标股价从10美元下调至4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发